Mirati raises $101M; Can-Fite gains fast track status;

@FierceBiotech: Aerie skyrockets on a mixed success in second PhIII glaucoma study. Article | Follow @FierceBiotech

@JohnCFierce: First on Fierce: OrbiMed sets its sights on a $950M blockbuster biotech fund. News | Follow @JohnCFierce

> San Diego-based Mirati Therapeutics ($MRTX) raised $101 million in a new stock offering. Release

> The FDA has granted fast track status to Can-Fite's liver cancer drug. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Pentax backs $8M+ round for electrosurgery startup Creo. Article | Follow @FierceMedDev

@EmilyWFierce: Report: Cancer drug spending fuels large increases in Medicare discount drug program. ICYMI from FiercePharma | Follow @EmilyWFierce

> Mobile health apps top 165K mark, with 300 clinical trials using them. More

> Zoll buys an Israeli wearable cardiac monitor maker for $35M. Article

> FDA beefs up testing for duodenoscope cleaning devices. Report

Pharma News

@FiercePharma: ViroVet spins out of Aratana with focus on livestock health. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: BMS' Opdivo guns for kidney cancer nod with FDA 'breakthrough' tag. Article | Follow @CarlyHFierce

> BMJ: New analysis shows increased suicide rates in teens taking GSK's Paxil. More

> Celgene's Abraxane takes another hit from cost-effectiveness gatekeepers. Story

> Newly vocal union targets Big Pharma's payments to AHA and its leaders. Article

Vaccines News

> Takeda joins consortium that accelerates R&D for malaria, TB vaccines. Item

> Vaxent and PREVENT kick off Strep A vaccine trials. More

> Emory team to look at GSK vax response as part of NIH research. Report

> FDA panel recommends Fluad, possibly the first U.S. boosted flu jab. Story

> J&J's Janssen strikes four-year, $28.5M government partnership to advance Ebola vaccine. Article

CRO News

> PRA adding 150 jobs amid Pennsylvania expansion push. Report

> Chiltern closes its Theorem buy, doubling its workforce. Item

> Accelovance inks a nonprofit partnership for melanoma trials. Article

> WuXi brings its genomic heft to Chinese patients with hospital pact. Story

> Evotec upsizes its 2015 projections after a string of partnering deals. Article

Pharma Manufacturing News

> Pfizer Chinese JV partner Zhejiang Hisun Pharma gets FDA warning letter. More

> Nexvet picks up biologics plant in Ireland. Item

> FDA castigates Indian drugmaker over mess at API plant. Report

> Hamburg's pick in line to take over as FDA commissioner. Story

> FDA sears maker of GolfersSkin Sunscreen in warning letter. Article

Pharma Asia News

> Taiwan's TWi Pharmaceuticals raises $87M via GDR in weak pricing. Report

> China's Yabao Pharmaceutical adds to a summer string of tie-ups. Item

> Dual-listed Benitec adds fourth site for hep C trials of TT-034. More

> Low-cost genomic sequencing on the slate for China with Veritas landing? Story

> India's Glenmark says breast cancer candidate GBR 1302 moving to PhI. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.